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Calpains are Ca 2+-dependent serine proteases that can regulate protein kinase C-mediated cellular events by cleaving 
the membrane-bound native enzyme to yield an activated cytosolic fragment. Inhibition of calpain by leupeptin may cauSe 
enhancement or inhibition of cellular functions depending on the nature of the protein kinase C reaction involved. We 
have studied the effects of leupeptin on platelet responses (aggregation, secretion, thromboxane BZ formation and intra- 
cellular CaZ+ and pH changes) induced by either thrombin, collagen or phorbol 1Zmyristate 13-acetate (TPA), which 
are known to activate protein kinase C by different mechanisms. Only thrombin-induced responses were inhibited by 
leupeptin. This suggests that the inhibitory effect of leupeptin is not due to antagonism of calpain in this system, but 
to direct interference with the proteolytic effect of thrombin. 
Leupeptin; Ca2+, intracellular; pH, intracellular; Thromboxane B2; (Platelet) 
1. INTRODUCTION 
It has been reported that the calpain inhibitor 
leupeptin [l] inhibits several thrombin-induced 
platelet responses, including aggregation, secre- 
tion, PIPz hydrolysis, protein phosphorylation and 
fibrinogen receptor expression [2,3]. In neutro- 
phils leupeptin enhances oxygen radical produc- 
tion and reduces exocytosis through a mechanism 
involving the inhibition of proteolysis of the 
membrane-attached protein kinase C [4]. The aim 
of the present work is to test whether or not a 
similar mechanism is responsible for the effects of 
leupeptin in platelets. Three different aspects of 
Correspondence address: A. Sanchez, Departamento de Bio- 
quimica y Biologia Molecular y Fisiologia, Facultad de 
Medicina, Universidad de Valladolid, 47005 Valladolid, Spain 
Abbreviations: TPA, phorbol 12-myristate 13-acetate; BCECF, 
2,7-biscarboxyethyl-5(6)-carboxyfluorescein; BSA, bovine serum 
albumin; ACD, acid-citrate dextrose; DG, diacylglycerol; PIPa, 
phosphatidylinositol 4,5bisphosphate; IPs, inositol 1,4,5-tris- 
phosphate; PLC, phospholipase C; PLAz, phospholipase AZ; 
TXBa, thromboxane BZ 
platelet activation, changes of intracellular Ca” 
levels ([Ca2’]i), intracellular pH (pHi), and throm- 
boxane AZ (TXA2) generation, were studied. 
Cellular responses uch as aggregation and secre- 
tion were also followed. Three different agonists 
which differ in their action mechanism, thrombin, 
collagen and phorbol 1Zmyristate 13-acetate 
(TPA), were used. Thrombin is a universal 
agonist, capable of inducing changes in all the 
parameters studied [5-71, collagen acts mainly 
through TXAZ generation [5], and TPA promotes 
direct activation of protein kinase C without modi- 
fying [Ca’+]i [8]. 
2. EXPERIMENTAL 
Platelet-rich plasma was obtained from freshly drawn 
titrated blood and centrifuged for 20 min at 350 x g. Platelets 
were resuspended at a concentration of 3 x 10’ cells/ml in 
nominally Ca ‘+-free standard medium with the following com- 
position (mM): 145 NaCl; 5 KCl; 1 MgS04; 10 glucose; 10 Na- 
Hepes, pH 7.4. This suspension was divided in two halves and 
cells were loaded with either 2 pM BCECF or 2 PM fura- by 
incubation for 45 min at 37°C with their respective esters 
(Molecular Probes, Junction City, OR, USA). The cell suspen- 
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sions were then diluted with two volumes of standard medium 
containing 1 mg/ml BSA and 2% ACD. The cells were 
sedimented by centrifugation and resuspended in fresh standard 
medium. Immediately before the corresponding experiment 
1 mM of either CaC12 or EGTA was added to each sample. 
Specific fluorescence was measured at lo* cells/ml at 37°C with 
continuous stirring. Calibration of the fura- signal was per- 
formed as described before [9] and that of BCECF was per- 
formed in a high-K medium containing 2 PM nigericin (a gift of 
Lilly Indiana de Espafia) as described previously [lo]. Aggrega- 
tion and ATP secretion was followed simultaneously in a 
Coulter lumi-aggregometer. Secretion of “C-serotonin [I I] was 
also studied in parallel in some experiments to check the ade- 
quacy of the lumi-aggregometer signal. Thromboxane BZ for- 
mation was assayed by radioimmunoassay using a specific 
antibody obtained from Diagnostics Pasteur. 
Washed platelets were incubated with lo-500 pM leupeptin 
(Sigma) for 10 min prior to agonist addition. It has been 
postulated that this 10 min incubation of washed platelets with 
leupeptin was needed to achieve intracellular permeation of this 
compound [12]. We find, however, that reducing this period to 
1 min did not modify the inhibitory pattern of leupeptin (results 
not shown). The final concentrations of agonists were 
0.1-5 U/ml thrombin (Calbiochem), 10 #g/ml collagen 
(Horm) and 100 nM TPA (Sigma). Stocks were prepared in 
buffer (thrombin and collagen) or dimethylsulphoxide (TPA). 
The amount of the latter solvent in the cell suspension was 
always below 0.2%. 
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3. RESULTS AND DISCUSSION 
Fig.lA shows the changes in [Ca2+]i induced by 
thrombin and collagen under control conditions 
(left) and after a 10 min treatment with 100 PM 
leupeptin (right). Fig. 1B illustrates pHi changes in- 
duced by thrombin and TPA in control (left) and 
leupeptin-treated cells (right). Only in thrombin- 
treated cells did leupeptin modify agonist-evoked 
changes in [Cali and pHi. Similar results were also 
obtained when aggregation and secretion were 
followed (data not shown). These results discount 
possible inhibition of protein kinase C by leupeptin 
in platelets since TPA-induced alkalinization is 
mediated by protein kinase C [6,7]. The increase in 
[Ca2+]i induced by collagen is mainly due to 
thromboxane generation through the cycloox- 
ygenase pathway [5]. The inability of leupeptin to 
affect [Ca2+]i responses induced by collagen would 
therefore suggest that it does not interfere with 
thromboxane formation. This was confirmed by 
quantitating the increase in TXBz induced by col- 
lagen and thrombin in the presence and absence of 
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Fig.1. Effects of leupeptin on agonist-induced changes in intracellular Ca*+ (A) and pH (B) in human platelets. Leupeptin (100 CM) 
was added 10 min before agonist addition. Experiments with collagen (10 ,ug/ml) were performed in medium containing 1 mM CaClz 
and those with thrombin (0.1 U/ml) or TPA (100 nM) in Ca’+-free medium. 
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leupeptin (table 1). Leupeptin inhibited the genera- 
tion of TXBz in thrombin-stimulated cells but did 
not have significant effect on the response to col- 
lagen. The lack of effect of leupeptin on collagen- 
induced TXBz generation excluded possible in- 
teractions of calpain with any of the enzymes in- 
volved in the process. This includes PLAz, DG 
lipase, cyclooxygenase or thromboxane synthetase. 
Furthermore these results indicate that leupeptin 
does not interfere with platelet receptors for TXAz 
v31. 
Fig.2 shows the effects of increasing leupeptin 
concentrations on the secretion induced by either 
thrombin or TPA. TPA-induced secretion was not 
significantly affected at any of the concentrations 
of leupeptin tested, reinforcing the idea that 
leupeptin does not inhibit a protein kinase C- 
mediated event. In contrast, leupeptin inhibited 
thrombin-induced secretion in a dose-dependent 
manner. The inhibition by leupeptin could be 
relieved by increasing the concentration of throm- 
bin suggesting a ‘competitive’ interaction. Sub- 
maximal inhibitions of secretion correlated well 
with the effect of leupeptin on thrombin-evoked 
[Ca2+]i and pHi changes (data not shown). 
The insensitivity of TPA- and collagen-induced 
platelet responses to leupeptin suggests that 
leupeptin does not interfere with intracellular cal- 
pains in platelets, in contrast with proposals in 
other cell systems [4]. It should then affect an early 
step in the interaction of thrombin with platelets. 
The ‘competitive’ nature of the thrombin- 
leupeptin interaction and the observation that 
preincubation with leupeptin is not necessary for 
Table 1 
Effects of leupeptin on the rise of thromboxane BZ formation 
induced by collagen or thrombin in human platelets 
Agonist Thromboxane BZ (ng/lOs cells) 
Control + Leupeptin 
Collagen 877 + 72 734 + 104 
Thrombin 161 + 46 27 + 5.5 
Data represent he increments in TXBt levels from the resting 
level of 46.5 * 8 ng/lO’ cells. Platelets were incubated for 
2.5 min with the agonist and then the cells were sedimented by 
centrifugation. Thromboxane BZ was determined in the 
supernatants. Other details as for fig.1. Values represent 
mean f SD of three experiments 
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Fig.2. Effects of leupeptin on ATP secretion induced by 
thrombin or TPA in human platelets. Thrombin concentration 
is indicated in the figure in U/ml. TPA concentration was 
100 nM. Note that the scale for leupeptin concentration is 
logarithmic. ATP secretion is expressed as percent of the 
maximal response obtained. Values are means f SD of at least 
three different experiments. Other details as in fig.1. 
inhibition of thrombin effects suggest hat the in- 
teraction takes place in the extracellular medium. 
Since it has been shown previously that leupeptin 
inhibits fibrinogen cleavage without interfering 
with the ability of thrombin to bind to its specific 
receptor [14], the most likely explanation for our 
results is that leupeptin produces a loss of pro- 
teolytic activity of thrombin which is crucial for 
the activation of the receptor. This mechanism 
would also explain the correlation among [Ca2+]i, 
pHi and secretion at submaximal inhibition values. 
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